NeOnc says FDA granted meeting on accelerated approval path for NEO100 in grade 4 astrocytoma

NeOnc Technologies says the FDA granted a meeting on the accelerated approval path for NEO100 in grade 4 astrocytoma, set for early January.

Detected & updated continuously · Source: Nebula